Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally
25.2.2026 08:07:00 CET | Business Wire | Press Release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH.
The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures.
Disruptive alternative to conventional processes
Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them.
The result is a high-efficiency production of clean hydrogen and syngas, while carbon is obtained as a high-purity industrial raw material that remains in material cycles. When biogenic feedstocks are used, the process enables a negative CO₂ footprint (Carbon Removal), as the carbon is permanently stored rather than released into the atmosphere. This modular approach allows for decentralized production directly at the point of consumption, significantly reducing transport costs and energy losses.
Strategic cooperation with RAG Austria AG
In parallel with the financing round, Graforce is deepening its partnership with energy storage company RAG Austria AG, which is providing targeted financial and industrial support for the further development of the methane plasma pyrolysis plant. The focus of the collaboration is on system optimization and industrial integration. This collaboration strengthens Graforce on its path to continuous industrial operation, increases plant efficiency, and supports the use of modular plants at locations with variable availability of renewable energies.
Use of Funds: Scale-up and market deployment
The funds will be used for technological advancement, the roll‑out of additional industrial plants, and international market development. Graforce plans to expand its production capacities to meet the rising demand from the steel, chemical, and transportation sectors.
Partner Statements
“With Graforce’s addition to our portfolio, Calderion strengthens its coverage of next-generation fuel value chains, combining CO₂ capture, plasma-based methane conversion and synthetic fuels. This enables integrated pathways from methane and CO₂ to low-carbon hydrogen and syngas, serving both industrial decarbonization and sustainable fuels for maritime and aviation. Graforce’s technology also offers natural hydrogen explorers a solution to valorize associated methane without CO₂ emissions,” explains Vincent Brillault, Founding Partner of Calderion.
“The flexibility to provide various product gases in a decentralized and emission-free manner closes a critical gap in the industrial value chain. We are contributing our project planning expertise to bring this technology to the global market,” adds Jens Rötteken, CEO of Terravent.
“This investment underscores the enormous potential of our plasmalysis technology for a sustainable energy transition. We look forward to working together to make our plasmalysis technology scalable and cost-effective,” says Dr. Jens Hanke, CEO of Graforce GmbH.
About the partners
Graforce GmbH – Pioneer of CO₂-free hydrogen and syngas technologies based on plasma pyrolysis, enabling the utilization of methane, biogas, flare and landfill gases as industrial resources. www.graforce.com
Calderion & Audacia – Initiated by Audacia, Calderion is an industrial deep-tech fund dedicated to scaling next-generation fuel technologies. Audacia is listed on Euronext Growth Paris. calderion.com | audacia.fr
Terravent – Investor and project developer with a focus on renewable energies and integrated hydrogen infrastructure. Over one gigawatt of projects realized in 25 years. www.terravent.de
Wen.Co.Invest – Oldenburg-based family office investing in innovative, sustainability‑oriented ventures for long‑term positive impact. www.wegasupport.de
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224703188/en/
Contacts
Media Contact: Dr. Jens Hanke, CEO, Graforce GmbH, Phone: +49 30 632222 110,
presse@graforce.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI: The New Insider Threat Facing Organizations25.2.2026 09:00:00 CET | Press Release
According to the Thales 2026 Data Threat Report, organizations across various markets including automotive, energy, finance and retail say the rapid pace of AI-driven transformation is now their biggest security challenge. Based on the report’s research, conducted by S&P Global 451 Research, 61% cite AI as their top data security risk. The concern is not only about malicious AI, but about the access it is being granted as it shifts from a tool to a trusted insider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225599723/en/ ©Thales As enterprises embed AI into workflows, analytics, customer service, and development pipelines, these systems are being granted broad, automated access to enterprise data, often with fewer controls than those applied to human users in a corporate environment. “Insider risk is no longer just about people. It is also about automated systems that have been trusted too quickly,” says Sebastien Can
Zuper and Vonage Reimagine Network Connectivity for Skilled Trades with Quality on Demand25.2.2026 09:00:00 CET | Press Release
Zuper, the AI operating system for the trades, and Vonage, part of Ericsson, have entered into a Memorandum of Understanding (MoU) to enter into a collaboration to integrate Vonage’s network APIs into the Zuper platform. The collaboration will provide Zuper with early access to Vonage network powered solutions, starting with Quality on Demand (QoD), where mobile network performance can be selectively applied to support critical field workflows, delivering improved latency, reliability, and connected experiences for mobile workforces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225852261/en/ QoD is the first advanced network API being integrated¹ and represents one component of a larger vision for mobile networks as a platform that aligns network behaviour with application intent as these capabilities continue to be exposed. The ambition is to provide Zuper with programmable mobile network capabilities, powered by Vonag
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press Release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press Release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press Release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom